Sanjivani Paranteral Ltd (SANJIVIN)

Loading page…

Sanjivani Paranteral Ltd (SANJIVIN) · mywealthgrid

About

Small-cap pharmaceutical company (market cap ₹236.59 Cr) with quarterly standalone revenues of ₹2.93–₹8.2 Cr. Profitability erratic until recent recovery; dividend paid Sep 2025.

Face value: ₹10

Market cap

₹203 Cr

P/E

143.1×

P/B

4.2×

Dividend yield

0.3%

ROE

16%

ROCE

19.3%

Debt / equity

0.19

OPM

14.5%

EPS (TTM)

₹1.2

Book value

₹39.4

52-week high

—

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

PE ratio 166.73 is extreme—verify if current earnings are unusually depressed or growth expectations are misaligned with fundamentals.
Quarterly revenue volatile (₹2.93–₹8.2 Cr range) with losses in five of eight quarters (2019–20)—understand causes of earnings lumpiness and sustainability.
1y return –13.08% against 52w high ₹254 shows recent underperformance—verify if operational deterioration or market repricing.
Zero FII ownership despite ROE 24.59% suggests institutional caution—identify what concerns large investors.

Generated analysis · source review pending

Growth drivers

Operating margin recovered from –11.27% (Dec 2019) to 20.27% (Mar 2021)—verify what drove operational efficiency gains.
Revenue recovered from ₹2.93 Cr (Dec 2019) to ₹7–8 Cr range (2020–21)—check sustainability and whether from organic growth or lumpy contracts.
ROE 24.59% shows capital deployed efficiently; verify whether earnings can sustain this return as company scales.
D/E 0.15 is low, providing capacity for capex or acquisitions if pursued—verify management's capital allocation strategy.

Generated analysis · source review pending

1,658 historical price candles were omitted because the exchange source has not been verified.

₹165.1-3.8%1Y

Quick read

rule-based

Pros

+Strong return on equity of 20.9% (3-yr avg)
+High return on capital employed of 25.1%
+Profit CAGR of 37.3% over the last 5 years
+Revenue CAGR of 20.9% over the last 5 years
+Comfortable interest coverage of 18.1×
+Dividend payout of 43.3% of profit

Cons

−Expensive at 143.1× trailing earnings

Research score

Structured signal from quality, growth, valuation and momentum.

53/100

Business quality: 63
Growth: 80

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Standalone figures · ₹ crore · years without a filed annual are summed from quarters

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	115	33	18	25	16	25	31	35	54	70	65
COGS	—	—	-26	-15	-9	15	12	19	28	40	42
Gross profit	—	—	—	—	—	10	18	17	26	30	23
	122	48	96	42	26	8	13	11	18	19	13
	-7	-16	-53	-2	-0	2	6	6	8	10	9
OPM %	-6%	-47.5%	-292.5%	-8.2%	-2%	8.5%	18.7%	15.9%	15.1%	14.8%	14.5%
Depreciation	—	—	—	—	1	1	1	1	1	1	1
Interest	9	5	0	0	1	0	0	0	0	1	1
	—	—	0	1	0	0	0	1	1	1	1
Profit before tax	-15	-17	-53	-2	-2	1	5	5	8	10	9
Tax	—	—	-0	—	—	-0	0	0	1	2	2
Tax %	—	—	-0.6%	—	—	-0.7%	0.6%	8.7%	18.6%	21.8%	25%
	-15	-17	-53	-2	-2	1	5	5	6	8	7
PAT margin %	-12.7%	-52.9%	-295.4%	-8.3%	-10.5%	5.7%	15.8%	12.7%	11.3%	11.6%	10.7%
EPS (₹)	-24.8	-29.3	-90	-3.5	-2.9	1.7	—	—	—	—	5.7
EPS adjusted (₹)	—	—	—	—	—	1.7	4.9	4.5	5.3	6.8	5.6
Annual report	Annual report for Mar 2016	Annual report for Mar 2017	Annual report for Mar 2018	Annual report for Mar 2019	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	—

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	9	10	10	12	12	12
Reserves	-53	-18	-13	16	26	36
Minority interest	—	—	—	0	—	0
	42	6	2	1	6	9
	22	20	22	15	21	21
Total equity & liabilities	19	18	21	43	65	78
	8	7	8	10	21	22
CWIP	—	—	—	—	—	—
Investments	0	0	0	0	3	5
	12	11	13	33	41	52
Total assets	19	18	21	43	65	78

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	1	9	5	-11	-0	-2
	-0	-1	-1	-12	-6	-4
	-0	-8	-4	23	6	7
Net cash flow	-0	0	-0	0	0	1
Free cash flow	0	8	4	-14	-11	-4
CFO / Operating profit %	27.1%	149%	83%	-130%	-2.3%	-16.5%

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Standalone figures

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	—	—	41%	59.8%	47.7%	47.7%	42.3%	35.3%
EBITDA margin %	-8.2%	-2%	8.5%	18.7%	15.9%	15.1%	14.8%	14.5%
EBIT margin %	-8.2%	-8.6%	5.1%	15.8%	13.4%	13.4%	13.9%	13.2%
PAT margin %	-8.3%	-10.5%	5.7%	15.8%	12.7%	11.3%	11.6%	10.7%
Working capital
Receivable days	—	—	96	59	20	32	87	62
Inventory days	—	—	22	52	105	125	94	83
Payable days	—	—	261	339	270	74	138	101
NWC days	—	—	-142	-229	-144	83	43	44
Leverage
Current ratio	—	—	0.16	0.35	0.37	2.08	1.86	2.24
Debt to EBITDA	—	—	19.58	1.05	0.44	0.12	0.54	0.97
Debt to equity	—	—	-0.93	-0.79	-0.81	0.03	0.15	0.19
Interest coverage	-3.3	-1.7	11.8	24.2	14.8	31.3	18.6	18.1
Asset turnover	—	—	1.3	1.67	1.69	1.25	1.08	0.83
Return ratios
Return on assets %	—	—	7.4%	26.5%	21.5%	14.2%	12.5%	8.8%
Return on capital employed %	—	—	-4%	-141.8%	-323.8%	26.4%	29.5%	19.3%
Return on equity %	—	—	-3.2%	-64%	-146.9%	22.1%	21.3%	14.3%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	32.34%	32.34%	27.67%	27.67%	27.67%	27.67%	28.87%	28.87%	31.2%	31.2%	31.26%	31.56%
FII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	8.16%	6.01%	9.7%	9.36%	6.25%	6.25%	6.15%	6.15%	6.03%	6.04%	6.04%	5.45%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	59.5%	61.65%	62.63%	62.97%	66.08%	66.08%	64.98%	64.98%	62.77%	62.76%	62.7%	62.99%
No. of shareholders	—	—	—	—	—	—	—	—	6,286	6,017	5,933	5,880

Promoter holding down 0.78 percentage points since Sep 2023.

16 deals · 12 Jan 2022 – 19 Feb 2025

Date	Client	Type	Venue	Side	Quantity	Price	Value
19 Feb 2025	MONIKA GARWARE	Bulk	BSE	Sell	2,27,509	₹243.44	₹5.54 Cr
26 Aug 2024	NEXT ORBIT VENTURES FUND	Bulk	BSE	Sell	2,00,000	₹290.00	₹5.80 Cr
22 Aug 2024	NEXT ORBIT VENTURES FUND	Bulk	BSE	Sell	1,00,000	₹280.46	₹2.80 Cr
20 Dec 2023	SUREKHA HARAN	Bulk	BSE	Sell	1,01,034	₹152.70	₹1.54 Cr
18 Sept 2023	SUREKHA HARAN	Bulk	BSE	Buy	50,000	₹100.05	₹0.50 Cr
15 Sept 2023	SETU SECURITIES PVT. LTD.	Bulk	BSE	Buy	50,000	₹100.06	₹0.50 Cr
12 Sept 2023	SUREKHA HARAN	Bulk	BSE	Buy	50,000	₹100.00	₹0.50 Cr
27 Mar 2023	WOODSTOCK SECURITIES PRIV ATE LTD	Bulk	BSE	Sell	55,966	₹27.02	₹0.15 Cr
24 Mar 2023	WOODSTOCK SECURITIES PRIV ATE LTD	Bulk	BSE	Sell	79,292	₹25.94	₹0.21 Cr
20 Mar 2023	NEXT ORBIT VENTURES FUND	Bulk	BSE	Sell	60,000	₹32.75	₹0.20 Cr

1–10 of 16

1 / 2

Mr. ASHWANI ANAMISHARAN KHEMKAExecutive Director-Chairperson-MD
Mr. SRIVARDHAN ASHWANI KHEMKAExecutive Director
Mrs. MONIKA AMIT SINGHANIANon-Executive - Independent Director
Mr. ABHAY MILAN SHAHNon-Executive - Independent Director
Mr. BASANT SHRIVASTAVANon-Executive - Independent Director
Mr. Pritesh JainChief Financial Officer
Mr. Ravikumar Venkatramuloo BogamCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Sanjivani Paranteral Ltd. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Annual reports

Investor Presentation and earnings call

May 2026Transcript AI Summary PPT REC
Feb 2026Transcript AI Summary PPT

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

1

Dividend dividend19 Sept 2025 · ex-date₹0.5

1

Board meeting to consider results14 Aug 2026

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

4 announcementsExport CSV

28 Sept 2026, 8:45 pmInsider Trading / SAST

Closure of Trading Window

Closure of Trading Window PDF

28 Sept 2026, 1:05 pmInsider Trading / SAST

Closure of Trading Window

Closure of Trading Window PDF

16 Sept 2026, 4:30 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Scrutinizer''s Report

AGM PDF

16 Sept 2026, 4:24 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Outcome of AGM

AGM PDF

Date	Category	Subject	Filing
28 Sept 2026, 8:45 pm	Insider Trading / SAST Closure of Trading Window	Closure of Trading Window	PDF
28 Sept 2026, 1:05 pm	Insider Trading / SAST Closure of Trading Window	Closure of Trading Window	PDF

Loading announcements…

Sanjivani Paranteral Ltd

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Annual reports

Investor Presentation and earnings call

Events

1

1

Announcements

Not in the F&O segment

No fund holdings on record

1

1

Compounded sales growth

Compounded profit growth

Return on equity

Announcements

Annual reports

Investor Presentation and earnings call

Sanjivani Paranteral Ltd

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Annual reports

Investor Presentation and earnings call

Events

Dividends1

Board meetings1

Announcements

Ratio timeline

Not in the F&O segment

No fund holdings on record

Dividends1

Board meetings1

Quarterly record

Bulk & block deals

Board and management

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

Announcements

Annual reports

Investor Presentation and earnings call

1

1

1

1